In the MAPK pathway, targeted therapies, such as BRAF-inhibitors (e.g., vemurafenib, dabrafenib) and MEK-inhibitors (e.g., trametinib), have been developed to specifically inhibit components of the MAPK pathway in melanomas. The gene discussed is BRAF; the disease is melanoma.